Rallybio Corp (RLYB) stock
RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.29−0.14 (-0.88%)
Close on Nov 17, 2026Market cap $82.32MP/E 3.4Yield –
Rallybio r&d expenses
Research and development expenses are spending on new products and technology.
Rallybio's R&D Expenses for the twelve months ending Sep 30, 2026 was $7.87M, down 66.3% year over year. For fiscal 2025 it was $19.60M, down 52.8% from the year before. The highest annual figure on record is $53.54M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.60M | -52.8% |
| FY2024 | Dec 31, 2024 | $41.51M | -22.5% |
| FY2023 | Dec 31, 2023 | $53.54M | +31.6% |
| FY2022 | Dec 31, 2022 | $40.69M | +51.2% |
| FY2021 | Dec 31, 2021 | $26.91M | +52.6% |
| FY2020 | Dec 31, 2020 | $17.63M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $584.00K | -85.9% |
| Q2 FY2026 | Jun 30, 2026 | $758.00K | -87.5% |
| Q1 FY2026 | Mar 31, 2026 | $2.87M | -49.9% |
| Q4 FY2025 | Dec 31, 2025 | $3.66M | -50.5% |
| Q3 FY2025 | Sep 30, 2025 | $4.14M | -49.7% |
| Q2 FY2025 | Jun 30, 2025 | $6.07M | -53.1% |
| Q1 FY2025 | Mar 31, 2025 | $5.73M | -55.7% |
| Q4 FY2024 | Dec 31, 2024 | $7.39M | -53.6% |
| Q3 FY2024 | Sep 30, 2024 | $8.24M | -38.0% |
| Q2 FY2024 | Jun 30, 2024 | $12.95M | -1.4% |
| Q1 FY2024 | Mar 31, 2024 | $12.94M | +15.5% |
| Q4 FY2023 | Dec 31, 2023 | $15.92M | +47.5% |
| Q3 FY2023 | Sep 30, 2023 | $13.29M | +9.7% |
| Q2 FY2023 | Jun 30, 2023 | $13.13M | +29.5% |
| Q1 FY2023 | Mar 31, 2023 | $11.20M | +46.5% |
| Q4 FY2022 | Dec 31, 2022 | $10.79M | +77.1% |
| Q3 FY2022 | Sep 30, 2022 | $12.11M | +144.2% |
| Q2 FY2022 | Jun 30, 2022 | $10.14M | +48.7% |
| Q1 FY2022 | Mar 31, 2022 | $7.65M | -15.4% |
| Q4 FY2021 | Dec 31, 2021 | $6.09M | -18.7% |
| Q3 FY2021 | Sep 30, 2021 | $4.96M | -3.3% |
| Q2 FY2021 | Jun 30, 2021 | $6.82M | +120.5% |
| Q1 FY2021 | Mar 31, 2021 | $9.04M | – |
| Q4 FY2020 | Dec 31, 2020 | $7.50M | – |
| Q3 FY2020 | Sep 30, 2020 | $5.13M | – |
| Q2 FY2020 | Jun 30, 2020 | $3.09M | – |
See a number that looks wrong?